New hope for Tough-to-Treat breast cancer: drug trial targets 'HER2-Zero' tumors
NCT ID NCT06750484
Summary
This study is testing a drug called trastuzumab deruxtecan (T-DXd) in adults whose advanced breast cancer has spread and has tested completely negative for a protein called HER2. The goal is to see if this drug, which combines a targeted antibody with a chemotherapy agent, can shrink tumors in these patients who have few other options. Researchers will also try to identify which patients are most likely to benefit from this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.